Compare Corning Incorporated (GLW) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Incyte Corporation — how do they compare? Corning Incorporated trades at $156.69 (market cap $131.65B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Corning Incorporated is far larger — about 5.8× Incyte Corporation's market cap, and Corning Incorporated pays a 0.73% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Incyte Corporation for 33 Days on average.
| GLW | INCY | |
|---|---|---|
Market Cap | $131.65B | $22.85B |
Volume | 8,992,522 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $255.79 | $129.93 |
52-Week Low | $78.03 | $83.80 |
Typical Hold Time | 36 Days | 33 Days |
Enterprise Value | $138.52B | $18.35B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $152.81, down 6.37% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $15.63B in 2025 and net income of $1.60B, alongside a recent $3B+ fiber supply deal with AT&T announced September 29, 2026. Analyst consensus is bullish with a $171.25 price target, though valuation ratios like a P/E of 70.43 appear elevated.
The outlook is positive given earnings beats and strategic deals, but risks include high valuation, patent litigation, and macroeconomic sensitivity. Upside hinges on execution of the AT&T contract and sustained demand for optical communications driven by AI and data growth.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
